Luke Maese, DO

Luke Maese, D.O., received his Bachelor’s degree in Human Biology from the University of Kansas and then went on to receive his degree in osteopathic medicine from Kansas City University. He completed his Pediatric residency at UPMC Children’s Hospital of Pittsburgh and Pediatric Hematology/Oncology fellowship at the University of Utah and Primary Children’s Hospital. He joined the faculty of the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology in 2015 where he currently serves as an Associate Professor on the Clinical Track. He cares for patients at both Primary Children’s Hospital (PCH) and Huntsman Cancer Institute (HCI).

Dr. Maese’s focus includes clinical care for children with malignant hematopoietic disorders and cancer predisposition syndromes. He serves as director for the pediatric Leukemia/Lymphoma and pediatric Cancer Genetics programs, as well as the director of the Clinical Trial Research Enterprise within the division of pediatric hematology/oncology at PCH. He is a member of the Family Cancer Assessment Clinic (FCAC) and of the Schiffman lab at HCI.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trials in pediatric acute lymphoblastic leukemia. He serves as a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.

Dr. Maese’s interests in investigation are in pediatric leukemia and translating the genomics of cancer to the pediatric oncology clinic. His research efforts are focused on the study of cancer predisposition syndromes and clinical trials in pediatric acute lymphoblastic leukemia. He serves as a member of the Experimental Therapeutics Program at HCI and is the primary investigator for several clinical trials investigating the role for novel diagnostic and therapeutic techniques in the treatment of pediatric cancer.